Tag: liquid biopsy for cancer diagnostics market size

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Liquid Biopsy For Cancer Diagnostics Market Expected To Reach $22.99 Billion By 2030 At 16.4% CAGR

The market for liquid biopsies in cancer diagnostics has experienced substantial expansion lately, projected to increase from $10.75 billion in 2025 to $12.52 billion in 2026, reflecting a compound annual growth rate (CAGR) of 16.4%. This recent growth trajectory is influenced by several factors, including the inherent limitations associated with traditional tissue biopsy methods, an escalating prevalence of lung and breast cancer diagnoses, the increasing uptake of molecular diagnostic tools for cancer, a heightened demand for detecting cancer in its nascent stages, and a surge in clinical investigations within the field of oncology diagnostics.

The market for liquid biopsies in cancer diagnostics is poised for substantial expansion over the coming period, projecting a rise to $22.99 billion by 2030, fueled by a compound annual growth rate of 16.4%. This projected increase is largely driven by the widening application of liquid biopsies in standard cancer screening protocols, a heightened emphasis on individualized cancer treatment strategies, greater utilization for tracking treatment efficacy, escalating investments in the field of cancer diagnostics, and an increased deployment in the detection of gastrointestinal and ovarian cancers. Key developments anticipated during this forecast timeframe encompass the expanding use of liquid biopsies for diagnosing lung cancer, a surge in the adoption of blood-based screening techniques for cancer, a growing need for continuous cancer monitoring, the broadening application scope of liquid biopsies across various cancer types, and a prevalent shift in clinical practice towards favoring less invasive diagnostic methods.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp

Liquid Biopsy For Cancer Diagnostics Market Demand Drivers: What Is Fueling Industry Growth?

The expanding prevalence of cancer is anticipated to be a significant catalyst for the advancement of the liquid biopsy market within the realm of cancer diagnostics. Cancer, a complex collection of diseases, can originate in virtually any part of the body as abnormal cells multiply without control, breaching their normal confines and subsequently metastasizing to distant sites or invading adjacent tissues. This escalating cancer burden underscores the necessity for advanced diagnostic tools like liquid biopsy, capable of facilitating early detection, assessing individual patient risk, and monitoring treatment efficacy. Liquid biopsy offers a comprehensive, real-time view of tumor evolution, including the identification of therapeutic targets and resistance mechanisms, by analyzing circulating tumor cells or their byproducts released from both primary and metastatic lesions, thus capturing the multifaceted nature of the disease. Supporting this trend, data from the National Cancer Institute indicated approximately 18.1 million cancer survivors in the U.S. as of May 2024, with projections suggesting this number will climb to 22.5 million by 2032 and anticipates a rise in new cancer cases to 29.9 million annually by 2040, accompanied by an estimated 15.3 million cancer-related fatalities, reinforcing the market’s upward trajectory due to increasing cancer incidence.

Liquid Biopsy For Cancer Diagnostics Market Segment Analysis Highlighting Growth Areas

The liquid biopsy for cancer diagnostics market covered in this report is segmented –

1) By Type: Product, Services

2) By Sample: Blood, Urine, Saliva

3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices

2) By Services: Testing Services, Analytical Services, Bioinformatics Services

Liquid Biopsy For Cancer Diagnostics Market Innovation Trends: Which Developments Are Transforming The Industry?

Key players in the liquid biopsy for cancer diagnostics sector are prioritizing the creation of groundbreaking technologies, specifically advanced liquid biopsy assays. These sophisticated diagnostic tools examine diverse elements within biological fluids like blood to identify and define unique cancer-related markers. As an illustration, in November 2023, Illumina Inc., a prominent American firm in the DNA sequencing field, unveiled ‘TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)’. This groundbreaking research assay enables non-invasive, thorough genomic analysis of circulating tumor DNA found in blood samples, aiming to streamline user implementation and deepen the understanding derived from cancer research.

Liquid Biopsy For Cancer Diagnostics Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the liquid biopsy for cancer diagnostics market are F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

Access The Complete Liquid Biopsy For Cancer Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

Liquid Biopsy For Cancer Diagnostics Market Largest Region By Revenue And Market Share

North Americawas the largest region in the liquid biopsy for cancer diagnostics market in 2025. Asia-Pacificis expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Liquid Biopsy For Cancer Diagnostics Market Expected To Reach $22.99 Billion By 2030 At 16.4% CAGR

The market for liquid biopsies in cancer diagnostics has experienced substantial expansion lately, projected to increase from $10.75 billion in 2025 to $12.52 billion in 2026, reflecting a compound annual growth rate (CAGR) of 16.4%. This recent growth trajectory is influenced by several factors, including the inherent limitations associated with traditional tissue biopsy methods, an escalating prevalence of lung and breast cancer diagnoses, the increasing uptake of molecular diagnostic tools for cancer, a heightened demand for detecting cancer in its nascent stages, and a surge in clinical investigations within the field of oncology diagnostics.

The market for liquid biopsies in cancer diagnostics is poised for substantial expansion over the coming period, projecting a rise to $22.99 billion by 2030, fueled by a compound annual growth rate of 16.4%. This projected increase is largely driven by the widening application of liquid biopsies in standard cancer screening protocols, a heightened emphasis on individualized cancer treatment strategies, greater utilization for tracking treatment efficacy, escalating investments in the field of cancer diagnostics, and an increased deployment in the detection of gastrointestinal and ovarian cancers. Key developments anticipated during this forecast timeframe encompass the expanding use of liquid biopsies for diagnosing lung cancer, a surge in the adoption of blood-based screening techniques for cancer, a growing need for continuous cancer monitoring, the broadening application scope of liquid biopsies across various cancer types, and a prevalent shift in clinical practice towards favoring less invasive diagnostic methods.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp

Liquid Biopsy For Cancer Diagnostics Market Demand Drivers: What Is Fueling Industry Growth?

The expanding prevalence of cancer is anticipated to be a significant catalyst for the advancement of the liquid biopsy market within the realm of cancer diagnostics. Cancer, a complex collection of diseases, can originate in virtually any part of the body as abnormal cells multiply without control, breaching their normal confines and subsequently metastasizing to distant sites or invading adjacent tissues. This escalating cancer burden underscores the necessity for advanced diagnostic tools like liquid biopsy, capable of facilitating early detection, assessing individual patient risk, and monitoring treatment efficacy. Liquid biopsy offers a comprehensive, real-time view of tumor evolution, including the identification of therapeutic targets and resistance mechanisms, by analyzing circulating tumor cells or their byproducts released from both primary and metastatic lesions, thus capturing the multifaceted nature of the disease. Supporting this trend, data from the National Cancer Institute indicated approximately 18.1 million cancer survivors in the U.S. as of May 2024, with projections suggesting this number will climb to 22.5 million by 2032 and anticipates a rise in new cancer cases to 29.9 million annually by 2040, accompanied by an estimated 15.3 million cancer-related fatalities, reinforcing the market’s upward trajectory due to increasing cancer incidence.

Liquid Biopsy For Cancer Diagnostics Market Segment Analysis Highlighting Growth Areas

The liquid biopsy for cancer diagnostics market covered in this report is segmented –

1) By Type: Product, Services

2) By Sample: Blood, Urine, Saliva

3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices

2) By Services: Testing Services, Analytical Services, Bioinformatics Services

Liquid Biopsy For Cancer Diagnostics Market Innovation Trends: Which Developments Are Transforming The Industry?

Key players in the liquid biopsy for cancer diagnostics sector are prioritizing the creation of groundbreaking technologies, specifically advanced liquid biopsy assays. These sophisticated diagnostic tools examine diverse elements within biological fluids like blood to identify and define unique cancer-related markers. As an illustration, in November 2023, Illumina Inc., a prominent American firm in the DNA sequencing field, unveiled ‘TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)’. This groundbreaking research assay enables non-invasive, thorough genomic analysis of circulating tumor DNA found in blood samples, aiming to streamline user implementation and deepen the understanding derived from cancer research.

Liquid Biopsy For Cancer Diagnostics Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the liquid biopsy for cancer diagnostics market are F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

Access The Complete Liquid Biopsy For Cancer Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

Liquid Biopsy For Cancer Diagnostics Market Largest Region By Revenue And Market Share

North Americawas the largest region in the liquid biopsy for cancer diagnostics market in 2025. Asia-Pacificis expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Liquid Biopsy For Cancer Diagnostics Market Expected To Reach $22.99 Billion By 2030 At 16.4% CAGR

The market for liquid biopsies in cancer diagnostics has experienced substantial expansion lately, projected to increase from $10.75 billion in 2025 to $12.52 billion in 2026, reflecting a compound annual growth rate (CAGR) of 16.4%. This recent growth trajectory is influenced by several factors, including the inherent limitations associated with traditional tissue biopsy methods, an escalating prevalence of lung and breast cancer diagnoses, the increasing uptake of molecular diagnostic tools for cancer, a heightened demand for detecting cancer in its nascent stages, and a surge in clinical investigations within the field of oncology diagnostics.

The market for liquid biopsies in cancer diagnostics is poised for substantial expansion over the coming period, projecting a rise to $22.99 billion by 2030, fueled by a compound annual growth rate of 16.4%. This projected increase is largely driven by the widening application of liquid biopsies in standard cancer screening protocols, a heightened emphasis on individualized cancer treatment strategies, greater utilization for tracking treatment efficacy, escalating investments in the field of cancer diagnostics, and an increased deployment in the detection of gastrointestinal and ovarian cancers. Key developments anticipated during this forecast timeframe encompass the expanding use of liquid biopsies for diagnosing lung cancer, a surge in the adoption of blood-based screening techniques for cancer, a growing need for continuous cancer monitoring, the broadening application scope of liquid biopsies across various cancer types, and a prevalent shift in clinical practice towards favoring less invasive diagnostic methods.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp

Liquid Biopsy For Cancer Diagnostics Market Demand Drivers: What Is Fueling Industry Growth?

The expanding prevalence of cancer is anticipated to be a significant catalyst for the advancement of the liquid biopsy market within the realm of cancer diagnostics. Cancer, a complex collection of diseases, can originate in virtually any part of the body as abnormal cells multiply without control, breaching their normal confines and subsequently metastasizing to distant sites or invading adjacent tissues. This escalating cancer burden underscores the necessity for advanced diagnostic tools like liquid biopsy, capable of facilitating early detection, assessing individual patient risk, and monitoring treatment efficacy. Liquid biopsy offers a comprehensive, real-time view of tumor evolution, including the identification of therapeutic targets and resistance mechanisms, by analyzing circulating tumor cells or their byproducts released from both primary and metastatic lesions, thus capturing the multifaceted nature of the disease. Supporting this trend, data from the National Cancer Institute indicated approximately 18.1 million cancer survivors in the U.S. as of May 2024, with projections suggesting this number will climb to 22.5 million by 2032 and anticipates a rise in new cancer cases to 29.9 million annually by 2040, accompanied by an estimated 15.3 million cancer-related fatalities, reinforcing the market’s upward trajectory due to increasing cancer incidence.

Liquid Biopsy For Cancer Diagnostics Market Segment Analysis Highlighting Growth Areas

The liquid biopsy for cancer diagnostics market covered in this report is segmented –

1) By Type: Product, Services

2) By Sample: Blood, Urine, Saliva

3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices

2) By Services: Testing Services, Analytical Services, Bioinformatics Services

Liquid Biopsy For Cancer Diagnostics Market Innovation Trends: Which Developments Are Transforming The Industry?

Key players in the liquid biopsy for cancer diagnostics sector are prioritizing the creation of groundbreaking technologies, specifically advanced liquid biopsy assays. These sophisticated diagnostic tools examine diverse elements within biological fluids like blood to identify and define unique cancer-related markers. As an illustration, in November 2023, Illumina Inc., a prominent American firm in the DNA sequencing field, unveiled ‘TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)’. This groundbreaking research assay enables non-invasive, thorough genomic analysis of circulating tumor DNA found in blood samples, aiming to streamline user implementation and deepen the understanding derived from cancer research.

Liquid Biopsy For Cancer Diagnostics Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the liquid biopsy for cancer diagnostics market are F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

Access The Complete Liquid Biopsy For Cancer Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

Liquid Biopsy For Cancer Diagnostics Market Largest Region By Revenue And Market Share

North Americawas the largest region in the liquid biopsy for cancer diagnostics market in 2025. Asia-Pacificis expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Liquid Biopsy For Cancer Diagnostics Market Between 2026 And 2030?

The liquid biopsy for cancer diagnostics market size has experienced rapid growth in recent years. This market is set to expand from $10.75 billion in 2025 to $12.52 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.4%. Historically, this growth has been fueled by limitations associated with tissue biopsy procedures, the increasing incidence of lung and breast cancer, the early adoption of molecular cancer diagnostics, a growing need for early-stage cancer detection, and rising clinical research in oncology diagnostics.

The liquid biopsy for cancer diagnostics market size is anticipated to experience substantial growth over the coming years. It is projected to expand to $22.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.4%. This expansion during the forecast period can be attributed to several factors, including the wider implementation of liquid biopsy in routine cancer screening, an increasing emphasis on personalized cancer care, its growing use in monitoring treatment responses, rising investments in cancer diagnostics, and its expanded application in gastrointestinal and ovarian cancers. Prominent trends expected in this period include the increased adoption of liquid biopsy for lung cancer diagnosis, a surge in the use of blood-based cancer screening methods, a heightened demand for real-time cancer monitoring, the broadening application of liquid biopsy across various cancer types, and a growing clinical preference for minimally invasive diagnostic approaches.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp

What Market Drivers Are Helping Shape The Liquid Biopsy For Cancer Diagnostics Market Expansion?

The increasing prevalence of cancer is anticipated to fuel the expansion of the liquid biopsy for cancer diagnostics market in the future. Cancer, a wide range of diseases, occurs when abnormal cells multiply uncontrollably in almost any body organ or tissue, exceeding their normal limits and either spreading to other areas or invading adjacent tissues. This condition heightens the demand for diagnostic methods like early detection of cancer or tumor recurrence, patient-specific risk evaluation, and treatment monitoring, allowing liquid biopsy to present a comprehensive view of the disease. This is because tumor cells or their products are released from all primary or metastatic tumor sites, offering detailed and current insights into tumor progression, therapeutic targets, and mechanisms of treatment resistance. For example, as reported by the National Cancer Institute, a US government body, in May 2024, approximately 18.1 million cancer survivors were in the United States. This number is predicted to grow to 22.5 million by 2032. Furthermore, by 2040, annual new cancer cases are projected to hit 29.9 million, with cancer-related fatalities expected to climb to 15.3 million. Consequently, the escalating incidence of cancer is boosting the growth of the liquid biopsy for cancer diagnostics market.

What Segment Categories Are Evaluated In The Liquid Biopsy For Cancer Diagnostics Market Study?

The liquid biopsy for cancer diagnostics market covered in this report is segmented –

1) By Type: Product, Services

2) By Sample: Blood, Urine, Saliva

3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices

2) By Services: Testing Services, Analytical Services, Bioinformatics Services

What Trends Are Driving Changes In The Liquid Biopsy For Cancer Diagnostics Market?

Major companies operating in the liquid biopsy for cancer diagnostics market are focusing their initiatives on developing innovative solutions, including advanced liquid biopsy assays. Such an assay is a sophisticated diagnostic test designed to analyze various components in a liquid biological sample, like blood or other bodily fluids, to detect and characterize specific biomarkers associated with cancer or other diseases. As an illustration, in November 2023, Illumina Inc., a US-based global leader in DNA sequencing, announced the launch of ‘TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)’. This product is a research assay created to enable noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) sourced from blood. The TSO 500 ctDNA v2 assay aims to simplify user integration and enhance the depth of insights obtainable for cancer research.

Which Companies Form The Competitive Landscape Of The Liquid Biopsy For Cancer Diagnostics Market?

Major companies operating in the liquid biopsy for cancer diagnostics market are F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

Access The Complete Liquid Biopsy For Cancer Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

Which Region Stands As The Largest Contributor To The Liquid Biopsy For Cancer Diagnostics Market?

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Liquid Biopsy For Cancer Diagnostics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12205&type=smp

Browse Through More Reports Similar to the Global Liquid Biopsy For Cancer Diagnostics Market 2026, By The Business Research Company

Liquid Biopsy For Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

Biopsy Devices Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Biopsy Devices Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Liquid Biopsy For Cancer Diagnostics Market Expected To Scale Between 2026 And 2030?

The liquid biopsy for cancer diagnostics market size has seen rapid growth in recent years. It is anticipated to grow from $10.75 billion in 2025 to $12.52 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 16.4%. This historical expansion can be attributed to factors such as limitations of tissue biopsy procedures, increasing incidence of lung and breast cancer, early adoption of molecular cancer diagnostics, growing need for early-stage cancer detection, and rising clinical research in oncology diagnostics.

The liquid biopsy for cancer diagnostics market is anticipated to experience substantial growth in the coming years, with projections indicating it will reach $22.99 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.4%. This expansion over the forecast period is primarily driven by the increased use of liquid biopsy in routine cancer screening, a heightened focus on personalized cancer care, its rising adoption in monitoring treatment responses, growing investments in cancer diagnostics, and its expanding application in gastrointestinal and ovarian cancers. Key trends during this period include the increasing integration of liquid biopsy in diagnosing lung cancer, the rising prevalence of blood-based cancer screening methods, an escalating demand for real-time cancer monitoring, the broadening application of liquid biopsy across multiple cancer types, and a growing clinical preference for minimally invasive diagnostics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp

Which Factors Are Influencing The Growth Of The Liquid Biopsy For Cancer Diagnostics Market?

The increasing incidence of cancer is anticipated to drive the expansion of the liquid biopsy for cancer diagnostics market in the future. Cancer refers to a broad spectrum of diseases that can manifest in nearly any organ or tissue when abnormal cells proliferate without control, surpassing their usual boundaries, and subsequently spreading to other organs or invading adjacent body parts. The prevalence of cancer underscores the demand for diagnostic procedures like early detection of cancer or tumor recurrence, personalized patient risk assessment, and treatment monitoring, allowing liquid biopsy to reveal the full scope of the disease as tumor cells or their products are shed from all metastatic or primary tumor sites, thereby offering comprehensive, real-time information on tumor cell evolution, therapeutic targets, and mechanisms of resistance to therapy. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported approximately 18.1 million cancer survivors in the United States. This number is projected to climb to 22.5 million by 2032. By 2040, new cancer cases each year are expected to reach 29.9 million, with cancer-related deaths estimated to increase to 15.3 million. Therefore, the rising occurrence of cancer is a key factor fueling the growth of the liquid biopsy for cancer diagnostics market.

How Is The Liquid Biopsy For Cancer Diagnostics Market Categorized Across Its Segment Groups?

The liquid biopsy for cancer diagnostics market covered in this report is segmented –

1) By Type: Product, Services

2) By Sample: Blood, Urine, Saliva

3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices

2) By Services: Testing Services, Analytical Services, Bioinformatics Services

Which Trends Are Influencing Demand In The Liquid Biopsy For Cancer Diagnostics Market?

Leading companies in the liquid biopsy market for cancer diagnostics are concentrating their efforts on creating innovative solutions, such as advanced liquid biopsy assays. An advanced liquid biopsy assay is a sophisticated and highly refined diagnostic test that examines various components in a liquid biological sample, like blood or other bodily fluids, to identify and characterize specific biomarkers linked to cancer or other diseases. For instance, in November 2023, Illumina Inc., a US-based global leader in DNA sequencing, announced the release of ‘TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)’. This is a research assay engineered to enable noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) derived from blood. The TSO 500 ctDNA v2 assay is designed to simplify integration for users and deepen the insights available for cancer research.

Which Firms Are Influencing Competition In The Liquid Biopsy For Cancer Diagnostics Market?

Major companies operating in the liquid biopsy for cancer diagnostics market are F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

Get The Full Liquid Biopsy For Cancer Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

Which Region Is The Top Contributor To The Liquid Biopsy For Cancer Diagnostics Market By Share?

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Liquid Biopsy For Cancer Diagnostics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

Browse Through More Reports Similar to the Global Liquid Biopsy For Cancer Diagnostics Market 2026, By The Business Research Company

Liquid Biopsy For Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

Biopsy Devices Market Report

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Biopsy Devices Market Report

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Liquid Biopsy For Cancer Diagnostics Market Over The 2026–2030 Period?

The liquid biopsy for cancer diagnostics market size has undergone rapid expansion in recent years. It is anticipated to increase from $10.75 billion in 2025 to $12.52 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.4%. The historical growth can be attributed to several factors including the constraints of tissue biopsy procedures, an increasing prevalence of lung and breast cancer, the early embrace of molecular cancer diagnostics, a heightened necessity for early-stage cancer detection, and the growing volume of clinical research in oncology diagnostics.

The liquid biopsy for cancer diagnostics market is anticipated to experience significant expansion over the coming years, projected to reach $22.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.4%. This projected growth is largely driven by factors such as the broader integration of liquid biopsy into standard cancer screening procedures, an increasing emphasis on individualized cancer treatments, its greater utilization for monitoring treatment effectiveness, escalating financial commitments in cancer diagnostics, and its expanding application in addressing gastrointestinal and ovarian cancers. Key trends expected during this period involve the increasing embrace of liquid biopsy for diagnosing lung cancer, a surge in the application of blood-based methods for cancer screening, a heightened need for continuous cancer monitoring, the proliferation of liquid biopsy applications across a wider spectrum of cancer types, and a growing medical inclination towards less invasive diagnostic techniques.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp

Which Major Factors Are Driving The Expansion Of The Liquid Biopsy For Cancer Diagnostics Market?

The growing occurrence of cancer is anticipated to drive the expansion of the liquid biopsy for cancer diagnostics market in the future. Cancer refers to a wide range of diseases that can arise in almost any body organ or tissue, characterized by the uncontrolled multiplication of abnormal cells that surpass their normal limits and can spread to other organs or invade adjacent tissues. The prevalence of cancer heightens the demand for diagnostic methods like early detection of cancer or tumor recurrence, individual patient risk assessment, and treatment oversight. Liquid biopsy fulfills this need by illustrating the complete progression of the disease, as tumor cells or their byproducts are released from all primary or metastatic tumor sites, offering comprehensive and current data on tumor cell changes, therapeutic goals, and how tumors resist treatment. For example, data from May 2024, provided by the National Cancer Institute, a US-based government agency, indicated approximately 18.1 million cancer survivors in the United States. This number is projected to increase to 22.5 million by 2032. Furthermore, by 2040, new cancer diagnoses annually are anticipated to reach 29.9 million, with cancer-related fatalities expected to grow to 15.3 million. Consequently, the escalating incidence of cancer is a key factor propelling the expansion of the liquid biopsy for cancer diagnostics market.

How Is The Liquid Biopsy For Cancer Diagnostics Market Segmented Across Key Categories?

The liquid biopsy for cancer diagnostics market covered in this report is segmented –

1) By Type: Product, Services

2) By Sample: Blood, Urine, Saliva

3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices

2) By Services: Testing Services, Analytical Services, Bioinformatics Services

What Industry Trends Are Redefining The Liquid Biopsy For Cancer Diagnostics Market?

Companies operating in the liquid biopsy for cancer diagnostics market are focusing their strategies on developing innovative solutions, including advanced liquid biopsy assays. An advanced liquid biopsy assay is a sophisticated and highly refined diagnostic test that examines various elements present in a liquid biological sample, such as blood or other bodily fluids, to detect and characterize particular biomarkers linked to cancer or other illnesses. For example, in November 2023, Illumina Inc., a US-based global leader in DNA sequencing, revealed the launch of ‘TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)’. This is a research assay specifically designed to enable noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) extracted from blood. The TSO 500 ctDNA v2 assay is intended to simplify integration for users and enhance the depth of insights available for cancer research efforts.

Who Are The Dominant Players Shaping The Liquid Biopsy For Cancer Diagnostics Market Landscape?

Major companies operating in the liquid biopsy for cancer diagnostics market are F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

Read the full liquid biopsy for cancer diagnostics market report here:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

Which Region Currently Holds The Largest Share Of The Liquid Biopsy For Cancer Diagnostics Market?

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Liquid Biopsy For Cancer Diagnostics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12205&type=smp

Browse Through More Reports Similar to the Global Liquid Biopsy For Cancer Diagnostics Market 2026, By The Business Research Company

Liquid Biopsy For Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

Biopsy Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Biopsy Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model